Technology

We create innovative solutions based on groundbreaking gene editing technology in humans for clinical use.

Product

Cryopreserved autologous hematopoietic stem cells with efficient and safe CCR5 knockout to generate an HIV-resistant immune system.

Investment

Vast perspectives for clinical use of our therapeutic innovations decisively makes the company an attractive investment case in the area of biotechnology and gene editing.

Our mission

To cure patients of HIV and HIV-associated life-threatening hematopoietic malignancies and relieve them from lifelong antiretroviral therapy.

Our team

AGCT is an R&D company that has united the leading specialists in clinical medicine, oncology, hematology, stem cell transplantation, cell therapy and molecular biology.

Marina Popova, MD, PhD

CEO & Founder

Marina Popova is a highly experienced physician and scientist on the field of hematology, oncology and cell therapy, hematopoietic stem cell transplantation. Dr. Popova is currently a senior research associate and Head of the HIV Programme at the Raisa Gorbacheva Memorial Research Institute of Children’s Oncology, Hematology and Transplantation. Dr. Popova is also an associate professor at the Hematology, Transfusiology and Transplantology Department, Pavlov First State Medical University of Saint Petersburg.

Alena Shakirova, MSc in Biology

Leading Researcher & Co-founder

Alena Shakirova is a highly experienced molecular biology specialist with focus on hematooncology. Currently Ms. Shakirova is a Lead Biologist, Laboratory of Transplantation and Molecular Hematology at Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Pavlov First State Medical University of Saint Petersburg.

Tatiana Gavrilenko

Project Manager

Tatiana's background includes biochemistry and foreign languages. For many years Tatiana has worked as an interpreter for international organizations, European missions and governmental institutions. She handled both administrative and translation tasks in different subjects, but with a particular focus on healthcare.

Vladislav Sergeev, MD

Chief Technology Officer & Co-founder

Dr. Sergeev has extensive expertise in cell processing (hematopoietic stem cells, lymphocytes, NK-cells, mesenchymal stem cells) for clinical needs (auto-, allo-hematopoietic stem cell transplantation and cell therapy). Currently Dr. Sergeev works at the Cell Cryopreservation Unit, HSC Quality Control Laboratory, Raisa Gorbacheva Memorial Research Institute of Children’s Oncology, Hematology and Transplantation, Pavlov First State Medical University of Saint Petersburg.

Kirill Lepik, MD, PhD

Chief Research Officer & Co-founder

Kirill Lepik has experience in chemotherapy and hematopoietic stem cell transplantation in patients with hematologic malignancies. Dr. Lepik has initiated a number of clinical trials of cancer immunotherapy at Raisa Gorbacheva Memorial Research Institute of Children’s Oncology, Hematology and Transplantation, Pavlov First State Medical University of Saint Petersburg. Dr. Lepik is a brilliant scientist with a large experience in molecular and cell biology and an enthusiastic researcher in the field of gene editing, nanomedicine and stem cells.

Mikhail Samsonov, MD, PhD

Chief Medical and Regulatory Affairs & Co-founder

Dr. Mikhail Samsonov has Ph.D. in Cardiology & Immunology and over 20 years of experience in variety of senior / executive roles in medical affairs and clinical operations at pharmaceutical giants - Executive Director of Regional Clinical Operations at Bristol-Myers Squibb Company overseeing EMEA and Asia Pacific regions, including such emerging markets in China, India, and Eastern Europe in BMS.

Partners

We acknowledge with gratitude the input of our reliable partners – research institutes and biotech companies – for providing access to top quality products and services, and the invaluable overall support of the Skolkovo Innovation Centre.